Healthcare technology Cue Health (Cue) has secured $30m in base funding and option from the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).
The funding will accelerate the development and regulatory validation of an over-the-counter and professional use Influenza and Multiplex Respiratory Pathogen diagnostic cartridges for the Cue Health Monitoring System.
Cue Health CEO Ayub Khattak said: “BARDA’s expertise in the development of advanced medical technologies will be a great asset to Cue as we spearhead a new approach to dealing with the persistent threats of influenza and other respiratory pathogens.”
The Cue Health Monitoring System centers around a connected diagnostic device, which enables a range of in-home and in-clinic diagnostics. The system uses a custom designed reader to test clinical samples in a disposable test cartridge and then sends the results to a mobile application.
The mobile application provides access to features including interventional components such as telemedicine consultations for consumers and prescribing capabilities for physicians. The Cue Influenza Cartridge will be focused on detecting Influenza A and B.
The Cue Multiplex Respiratory Pathogen Cartridge will be a multiplex assay capable of detecting and differentiating between multiple respiratory pathogens.
Source: Company Press Release.